Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AUPH
stocks logo

AUPH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
74.86M
+25.04%
0.217
+2066.7%
75.30M
+20.55%
0.193
+20.83%
77.77M
+11.08%
0.203
+27.08%
Estimates Revision
The market is revising Upward the revenue expectations for Aurinia Pharmaceuticals Inc. (AUPH) for FY2025, with the revenue forecasts being adjusted by 3.81% over the past three months. During the same period, the stock price has changed by 23.47%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.81%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+17.83%
In Past 3 Month
Stock Price
Go Up
up Image
+23.47%
In Past 3 Month
Wall Street analysts forecast AUPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUPH is 16.60 USD with a low forecast of 13.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AUPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUPH is 16.60 USD with a low forecast of 13.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 15.310
sliders
Low
13.00
Averages
16.60
High
21.00
Current: 15.310
sliders
Low
13.00
Averages
16.60
High
21.00
Leerink
Outperform -> Market Perform
downgrade
$16
2025-12-03
New
Reason
Leerink
Price Target
$16
2025-12-03
New
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Aurinia Pharmaceuticals to Market Perform from Outperform with a $16 price target.
Leerink
Outperform
to
Market Perform
downgrade
$15 -> $16
2025-12-03
New
Reason
Leerink
Price Target
$15 -> $16
2025-12-03
New
downgrade
Outperform
to
Market Perform
Reason
Leerink downgraded Aurinia Pharmaceuticals to Market Perform from Outperform with a price target of $16, up from $15. While Aurinia has done well with the commercialization of Lupkynis in lupus nephritis, the product is unlikely to be as big as the firm originally thought and there is some uncertainty regarding the tail of this asset, the analyst tells investors in a research note. Additionally, while Leerink views the aritinercept data favorably, it is coming from behind in a crowded development landscape, and the firm lacks visibility into its differentiation and competitive moat.
Jefferies
Hold
to
Buy
upgrade
$10 -> $21
2025-11-07
Reason
Jefferies
Price Target
$10 -> $21
2025-11-07
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Aurinia Pharmaceuticals to Buy from Hold with a price target of $21, up from $10. The company's commercial performance with Lupkynis has driven a strong balance sheet and positive cash flow, the analyst tells investors in a research note. The firm also sees Aurinia's BAFF/APRIL inhibitor aritinercept as "under-the-radar" with a "derisked" mechanism of action. The drug should get more attention as Aurinia announced a development path in early 2026, contends Jefferies.
RBC Capital
Outperform
to
Sector Perform
downgrade
$9 -> $15
2025-11-04
Reason
RBC Capital
Price Target
$9 -> $15
2025-11-04
downgrade
Outperform
to
Sector Perform
Reason
RBC Capital downgraded Aurinia Pharmaceuticals to Sector Perform from Outperform with a price target of $15, up from $9. The firm says the shares have doubled over the last 12 months due to stronger than expected Lupkynis sales and improved operating leverage. RBC no longer believes the shares "carry an asymmetric risk/reward outlook." It wants more clarity on aritinercept's future development path before again recommending the shares.
H.C. Wainwright
Arthur He
initiated
$17
2025-07-30
Reason
H.C. Wainwright
Arthur He
Price Target
$17
2025-07-30
initiated
Reason
H.C. Wainwright analyst Arthur He assumed coverage of Aurinia Pharmaceuticals with a Buy rating and $17 price target. Aurinia is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, the analyst tells investors in a research note. The firm believes has a "solid and sustainable" foundation with its lupus nephritis franchise.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aurinia Pharmaceuticals Inc (AUPH.O) is 18.90, compared to its 5-year average forward P/E of 2.85. For a more detailed relative valuation and DCF analysis to assess Aurinia Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.85
Current PE
18.90
Overvalued PE
40.07
Undervalued PE
-34.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.51
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
44.97
Undervalued EV/EBITDA
-39.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.25
Current PS
0.00
Overvalued PS
19.50
Undervalued PS
1.01
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AUPH News & Events

Events Timeline

(ET)
2025-11-04
06:14:28
Aurinia Pharmaceuticals increases FY25 revenue forecast to $275M-$280M, up from $260M-$270M
select
2025-11-04
06:13:40
Aurinia Pharmaceuticals Announces Q3 Earnings Per Share of 23 Cents, Exceeding Consensus Estimate of 16 Cents
select
2025-11-03 (ET)
2025-11-03
06:34:04
FDA Official Steps Down Amid Lawsuit from Aurinia Pharmaceuticals, According to WSJ
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
12-01Yahoo Finance
Examining Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation Following Recent Increase in Share Price

  • Recent Stock Performance: Aurinia Pharmaceuticals (AUPH) has seen a significant stock surge, with shares up 22% in the last month and 84% year-to-date, driven by positive sentiment around its LUPKYNIS treatment and autoimmune drug pipeline.

  • Valuation Insights: The current share price of $16.12 is close to the fair value estimate of $16.50, indicating that analyst forecasts are influencing price dynamics, but the high price-to-earnings ratio of 27.3x suggests a valuation premium that could pose risks if growth slows.

  • Investor Confidence: Share repurchases exceeding $138 million and strong operating cash flow reflect confidence in future earnings, creating potential catalysts for improved earnings per share.

  • Risks and Considerations: Despite the optimistic outlook, reliance on LUPKYNIS and uncertainties in the drug pipeline development could challenge future growth, warranting caution among investors.

[object Object]
Preview
8.0
11-24NASDAQ.COM
Inaugural Week of AUPH Options Trading for July 2026

  • Put Contract Overview: The $15.00 put contract for AUPH has a bid of $1.35, allowing investors to buy shares at a cost basis of $13.65, which is attractive compared to the current price of $15.89. There is a 66% chance the contract may expire worthless, offering a potential 9.00% return on cash commitment.

  • Call Contract Overview: The $18.00 call contract has a bid of $1.40, and if shares are purchased at $15.89 and the call is sold, it could yield a total return of 22.09% if exercised by July 2026. There is a 47% chance this contract may also expire worthless, providing an 8.81% additional return.

  • Volatility Insights: The implied volatility for the put contract is 70%, while for the call contract it is 66%. In contrast, the actual trailing twelve-month volatility is calculated at 48%.

  • YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 13.98% annualized return if it expires worthless, and the call offering a 13.69% annualized return under similar conditions.

[object Object]
Preview
4.0
11-08Yahoo Finance
Aurinia Pharmaceuticals Stock Increases Following Jefferies Upgrade
  • Stock Performance: Aurinia Pharmaceuticals (AUPH) shares increased by 4.4% during recent Friday trading.
  • Analyst Upgrade: The rise in stock price followed an upgrade from Jefferies, indicating positive market sentiment.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aurinia Pharmaceuticals Inc (AUPH) stock price today?

The current price of AUPH is 15.31 USD — it has increased 2.68 % in the last trading day.

arrow icon

What is Aurinia Pharmaceuticals Inc (AUPH)'s business?

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

arrow icon

What is the price predicton of AUPH Stock?

Wall Street analysts forecast AUPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUPH is 16.60 USD with a low forecast of 13.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aurinia Pharmaceuticals Inc (AUPH)'s revenue for the last quarter?

Aurinia Pharmaceuticals Inc revenue for the last quarter amounts to 73.47M USD, increased 8.41 % YoY.

arrow icon

What is Aurinia Pharmaceuticals Inc (AUPH)'s earnings per share (EPS) for the last quarter?

Aurinia Pharmaceuticals Inc. EPS for the last quarter amounts to 0.23 USD, increased 130.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aurinia Pharmaceuticals Inc (AUPH)'s fundamentals?

The market is revising Upward the revenue expectations for Aurinia Pharmaceuticals Inc. (AUPH) for FY2025, with the revenue forecasts being adjusted by 3.81% over the past three months. During the same period, the stock price has changed by 23.47%.
arrow icon

How many employees does Aurinia Pharmaceuticals Inc (AUPH). have?

Aurinia Pharmaceuticals Inc (AUPH) has 130 emplpoyees as of December 05 2025.

arrow icon

What is Aurinia Pharmaceuticals Inc (AUPH) market cap?

Today AUPH has the market capitalization of 2.02B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free